| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Needham analyst Ryan Macdonald initiated coverage on Hims & Hers Health Inc. (NYSE:HIMS) at a Buy rating with a price target of $24.
The analyst writes that, despite increased stock volatility with its entry into the compounded GLP-1 market, he anticipates a positive impact on HIMS’s fundamentals and sees strong growth potential.
With the weight loss market valued at around $373 billion, HIMS is well-positioned to capitalize on this opportunity, addressing key barriers of cost and access to treatment, adds the analyst.
Macdonald says that HIMS is not solely dependent on GLP-1; the company is already growing at over 40% with revenues exceeding $1 billion, and it has multiple growth drivers and margin expansion opportunities through higher acuity care and personalized, margin-accretive products.
The analyst expects EBITDA of $147.6 million in FY24 and $233.1 million in FY25.
This month, the company reported quarterly earnings of six cents per share, which beat the analyst consensus estimate of three cents. Sales of $315.648 million beat the analyst consensus estimate by 5.24%.
Hims & Hers expects third-quarter revenue in a range of $375 million-$380 million and full-year revenue of $1.37 billion-$1.4 billion.
Investors can gain exposure to the stock via Amplify ETF Trust Amplify Online Retail ETF (NYSE:IBUY) and Invesco Dorsey Wright Healthcare Momentum ETF (NASDAQ:PTH).
HIMS Price Action: Hims & Hers Health shares are down 0.12% at $16.55 at publication Thursday.
Read Next:
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Courtesy of Hims & Hers Health, Inc.
